FDA Clears Tezacaftor/Ivacaftor Combo for Cystic Fibrosis

Symdeko is for people aged 12 years and older who have two copies of the F508del mutation in the CFTR gene or who have at least one mutation that is responsive to tezacaftor/ivacaftor.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply